40 results about "Tocopherol polyethylene glycol succinate" patented technology

The invention relates to a powdered tocopheryl polyethylene glycol succinate (TPGS) having an average particle size of less than about 1000 microns. In one embodiment, the powdered tocopheryl polyethylene glycol succinate is prepared by a process that includes atomizing a fluidic tocopheryl polyethylene glycol succinate into an environment suitable for solidifying the atomized tocopheryl polyethylene glycol succinate. In another embodiment, the powdered tocopheryl polyethylene glycol succinate is prepared by a process of applying a force to a solid tocopheryl polyethylene glycol succinate starting material that is sufficient to produce a powdered product.

The invention belongs to the technical field of medicines, and discloses an oleanolic acid nanometer suspension and a preparation method thereof. The curative effect of oleanolic acid is restricted because oleanolic acid has small solubility in water and low oral bioavailability. The oleanolic acid nanometer suspension of the invention is characterized by comprising oleanolic acid, tocopherol polyethylene glycol succinate 1000 and polyethylene glycol 4000 with a mass ratio of 10-5:1-2:1-2. The preparation method of the nanometer suspension is mild in condition, simple and controllable; and oleanolic acid in the prepared nanometer suspension has higher oral bioavailability.

A nano-pharmaceutical formulation, comprising pumpkin seed oil; D-α-tocopheryl polyethylene glycol succinate (TPGS); and polyethylene glycol (PEG) 200 is provided. Additional cardioprotective therapies such as quercetin may be included in the formulation. Methods of treating cardiac dysfunction by administering the formulation are also provided.

The invention relates to the field of Chinese medicine preparation, in particular to a method for preparing tripterine nano structure lipid carrier containing traditional Chinese medicine monomer and application of the tripterine nano structure lipid carrier in preparation of transdermal drugs used for treating psoriasis, rheumatoid arthritis, skin cancer and breast cancer. The tripterine nano structure lipid carrier is characterized by comprising the following components in parts by weight: 1 part of tripterine, 5-100 parts of mixed lipid, 0.5-10 parts of phospholipid, 0.1-15 parts of poloxamer-188 and 0.5-10 parts of vitamin E and tocopherol polyethylene glycol succinate, wherein the mixed lipid is composed of solid lipid monoglycerine and liquid lipid octylic acid / caprin according to the weight ratio of 1: 0.1-10: 1. Tripterine is prepared into the nano structure lipid carrier, the tripterine nano structure lipid carrier in a semi-solid or liquid preparation form is applied in a transdermal way, bioavailability of the tripterine can be improved, toxic response of tripterine can be reduced, and the nano structure lipid carrier provided by the invention has great clinical application value in the improvement of the treatment effect of tripterine.

A solid composition suitable for forming into a tablet includes a pharmaceutically active substance in an amount sufficient to provide a therapeutic effect when administered; from about 0.2 to about 15 weight %, based on the total weight of the composition, of a water-soluble preparation of a fat-soluble vitamin; and from about 10 to 80 weight %, based on the total weight of the composition, of an excipient. Another aspect of the present invention is method for making the solid composition.

The present invention relates to an oral pharmaceutical composition and a preparation method therefor, the oral pharmaceutical composition comprising an ionic bond complex consisting of teriparatide, deoxycholic acid, N [alpha]-deoxycholyl-L-lysyl methyl ester (N [alpha]-deoxycholyl-L-lysyl methyl ester, DCK), and D-[alpha]-tocopherol polyethylene glycol 1000 succinate (D-[alpha]-tocopherol polyethylene glycol 1000 succinate), the ionic bond complex comprising at least one compound selected from the group consisting of N [alpha]-deoxycholyl-L-lysyl methyl ester, N [alpha]-tocopherol polyethylene glycol 1000 succinate, N [alpha]-tocopherol polyethylene glycol 1000 succinate, N [alpha]-tocopherol polyethylene glycol 1000 succinate, N [alpha]-tocopherol polyethylene glycol 1000 succinate, N [alpha]- The oral pharmaceutical composition provided by the invention can improve the intestinal mucosa permeability and oral administration bioavailability of teriparatide and improve patient compliance, and can be used for treating osteoporosis.

The invention discloses a paclitaxel mixed micelle preparation, comprising 100 to 300 milligram of tocopherol polyethylene glycol succinate 1000 (TPGS), 0 to 50 milligram of phosphatide, 0.5 milliliter of anhydrous ethanol and 6 milligram of paclitaxel. The preparation method is as follows: the TPGS is dissolved in the anhydrous ethanol, or the TPGS and the phosphatide are dissolved in the anhydrous ethanol; the paclitaxel is added and dissolved under stirring; the mixture is filtered with a millipore filtration of 0.22 micrometer so as to obtain the paclitaxel mixed micelle preparation. In the invention, the TPGS and the phosphatide are used to form mixed micelles which have good stability and little toxic and side effects; the preparation method is simple and practicable, having a good application prospect. Compared to the prior art, polyoxyethylene castor oil in conventional prescription is substituted in the invention, thereby reducing toxic side effects of paclitaxel injections and greatly enhancing the safety of the injections on condition that solubility is guaranteed.

A pharmaceutical composition comprising:(a) a medium system, comprising a first component, a second component and a third component, wherein the first component is a phosphate buffered saline, the second component is selected from the group consisting of vegetable oils, animal oils, fatty acids and combinations thereof, and the third component is selected from the group consisting of polyethylene glycol, dimethyl sulfoxide (DMSO), ethanol, polypropylene glycol, polysorbate, polyoxyethylated vegetable oil, ethyl acetate, 2-hydroxyethyl 12-hydroxyoctadecanoate, tocopheryl polyethylene glycol succinate and combinations thereof; and(b) n-butylidenephthalide (BP).

The invention belongs to the technical field of medicines, and discloses an oleanolic acid nanometer suspension and a preparation method thereof. The curative effect of oleanolic acid is restricted because oleanolic acid has small solubility in water and low oral bioavailability. The oleanolic acid nanometer suspension of the invention is characterized by comprising oleanolic acid, tocopherol polyethylene glycol succinate 1000 and polyethylene glycol 4000 with a mass ratio of 10-5:1-2:1-2. The preparation method of the nanometer suspension is mild in condition, simple and controllable; and oleanolic acid in the prepared nanometer suspension has higher oral bioavailability.

The invention provides cabazitaxel long-circulation liposome injection and a preparation method thereof. The cabazitaxel long-circulation liposome injection comprises cabazitaxel or a pharmaceutically acceptable salt thereof, tocopherol polyethylene glycol succinate, distearoyl-phosphatidylethanolamine-polyethylene glycol-maleimide and phospholipid. The cabazitaxel long-circulation liposome injection is prepared by a film method. The liposome not only has the advantages of reduced toxicity, simple and convenient clinical use and improved bioavailability, but also has good stability of storage and use.

The invention discloses a preparation method for water-soluble natural vitamin E. the method comprises the steps that chloromethylated polystyrene resin and PEG1000 serve as raw materials, alkali serves as a catalyst, and reaction is carried out in an organic solvent at 45-135 DEG C so as to obtain PEG1000-loaded resin; under the action of the catalyst, 4-dimethylaminopyridine (DMAP) and tetrahydrofuran, water division reflux reaction is carried out on the PEG1000-loaded resin and d-alpha-tocopherol succinate so as to obtain TPGS-loaded resin; and after the TPGS-loaded resin is soaked by usingmethylbenzene, ethanol, palladium carbon and pyridoxal phosphate are added, and under the atmosphere of 0.8-1.5 MPa of hydrogen , stirring is carried out for reaction for 24 hours at the temperatureof 100-110 DEG C so as to obtain d-alpha-tocopherol polyethylene glycol succinate. According to the synthetic method, the yield of TPGS can reach 97.8%, the TPGS monoester content is 98.6%, and the TPGS diester content is 0.

This invention relates to an oral formulation containing an effective amount of the compound of the following formula I:d-alpha-tocopheryl polyethylene glycol 1000 succinate (“TPGS”); and 2-(2-ethoxyethoxy)ethanol (“Transcutol”). R1 through R4 and n are defined herein. Also disclosed is a method of treating cancer by administering this formula to a subject orally.

The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitorsEspecially, the present invention relates to a pharmaceutical composition comprising an A2A inhibitor of Formula (I) and a lipid carrier such as lauroyl macrogol-32 glycerides, D-α-tocopherol-polyethylene glycol-1000 succinate or a mixture thereof. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancers. The present invention also relates to a combination comprising an A2A receptor inhibitor of Formula (I) and an anticancer agent. The anticancer agent is for example an immunotherapeutic agent, such as a checkpoint inhibitor. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination. Additionally, the combination of the invention is particularly useful for the treatment and / or prevention of cancers.